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Introduction
Neurotrophic factors have been shown to have the potential to promote survival and regeneration 
of neurons. The three major groups of neurotrophic factors are subcategorized into neurotrophins, 
glial- cell derived neurotrophic factor family ligands (GFLs), and neurocytokines. Neurotrophins 
include nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) and others, such as 
neurotrophin 3 (NT3) and neurotrophin 4/5 (NT4/5). GFLs also belongs to the transforming growth 
factor beta (TGF-β) family, and GFLs consist of GDNF, neurturin, artemin and persephin [1]. 
Neurocytokines include ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF). 
Similar to other neurotrophic factors, CNTF has been shown to play an important role in promoting 
survival and inducing differentiation of nerve cells. CNTF was first isolated from chick embryonic 
ciliary ganglionic neurons [2]. It belongs to the interleukin (IL) 6cytokine family which includes IL-
6, IL-11, oncostatin M, cardiotrophin 1 and LIF [3]. The IL-6 type cytokines share a common gp130 
receptor subunit, and signal principally through the Janus tyrosine kinase‐signal transducer and 
activator of transcription (JAK/STAT) pathway [4-6]. CNTF is widely expressed in the brain, spinal 
cord and ciliary ganglia [7]. CNTF deficient mice develop normally and thrive. When the sciatic 
nerve was damaged in a sciatic nerve crush experiment, the CNTF knockout mice which underwent 
sham surgery had no change in walking compared to the wild type animals. However, the recovery 
from the sciatic nerve injury was significantly impaired in the CNTF knockout mice. These results 
suggest that CNTF is not essential for neural development but acts in response to injury [8].
Exogenous CNTF is shown to be neuroprotective and it improves neuronal regeneration. There 
are many clinical trials studying the therapeutic use of CNTF in neurodegenerative diseases. The 
majority of the trials are treating different types of retinal neurodegeneration [9-11]. CNTF has 
also been implicated in treating Huntington’s disease [12] and amyotrophic lateral sclerosis (ALS) 
[13,14]. Since the half-life of CNTF is only a couple of minutes, researchers have also investigated 
different delivery methods, such as including encapsulated cell intraocular implants [15], in 
order to enhance the effect of CNTF in patients. Human Dental Pulp Stem cells (DPSCs) were 
first isolated from the third molars [16]. DPSCs are mesenchymal cells in origin. They are able to 
form single colonies in culture, self-renewal in vivo, and demonstrate osteoblastic, chondroblastic, 
odontoblastic, cementoblastic, adipogenic, angiogenic and neurogenic differentiation potentials 
[17-19]. The proliferation rate of DPSCs are higher than bone marrow derived mesenchymal stem 
cells, making them a potential source for tissue regeneration [20].DPSCs have been shown to 
promote functional recovery of a completely transected spinal cord [21], induce chemo-attraction 
of host avian trigeminal ganglion axons[22], and when differentiated into supportive glial cells, have 
been shown to secrete significantly higher levels of neurotrophic factors[23]. Many reports have 
shown that dental pulp cells from murine and human both produce neurotrophic factors [21,24]. 
Specifically the mRNA of, NGF, BDNF, GDNF, NT3 and NT4/5 were seen in the inner dental 
epithelium and dental follicle cells in developing human teeth [25-28].
Every time a tooth is prepared for a filling, there is inflammation and thermal trauma which 
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Abstract
Neurotrophic factors have long been considered growth factors that promote survival and growth of 
various neuronal tissues. Recent studies showed that neurotrophic factors are also present in dental 
pulp and periodontal ligament. This paper reviews the literature about the ciliary neurotrophic 
factor (CNTF), a member of the neurotrophic factor family, and indicates the potential clinical 
application of CNTF in dental stem cell therapy.
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can lead to death of the nerve in the pulp space of the tooth. If CNTF 
can reduce inflammation post injury to the tooth, it could reduce the 
need for further treatment. Nerve damage and spontaneous necrosis 
of a tooth ultimately requires a root canal therapy treatment in order 
to stabilize and fix the problem. If we can harness the potential nerve 
survival and regeneration through the use of neurotrophic factors 
when nerve damage is sustained, it could decrease the necessity for 
root canal treatment. When orthognathic jaw surgery, periodontal 
surgery, and oral surgery is done, a potential risk is permanent loss of 
sensory innervation to that area because of the nerve damage that is 
done. DPSC therapies along with neurotrophic factors such as CNTF 
have the potential to be good candidates for neuroregenerative therapy 
and to be able to give natural sensory feeling back to the patient to 
increase the quality of life. The biggest challenge to nerve regenerative 
treatment in the sensory nervous system is that it is extremely 
difficult to quantify if an animal has lost and regained feeling in an 
area with sensory nerve damage. Many of the other studies regarding 
neuroregeneration using neurotrophic factors have looked at motor 
neuron degenerative diseases that give us quantifiable measurements. 
The potential application with regenerative therapy utilizing 
stem cells for regenerative dentistry could potentially have a lasting 
impact on the future of dentistry. DPSCs are slowly becoming 
increasingly studied due to the potential of their regenerative effects. 
CNTF as a neurotrophic factor has also been studied for its use in 
neurodegenerative diseases. Characterization of the effects of up 
regulating CNTF in DPSCs as well as seeing its effect on inflamed 
DPSCs would be the first step in determining the overall effects of 
CNTF and DPSC use for regenerative dentistry. Due to the fact that 
CNTF has already been studied in clinical trials for neurodegenerative 
diseases and DPSCs have been studied for neuroregeneration in 
animal models, they are both promising candidates for regenerative 
dentistry.
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